New Enterprise Associates related stories
All articles and analysis
Family care website Care.com expects to raise up to $86 mln in IPO - ReutersJan 10 (Reuters) - Care.com, an online marketplace for family care services, is seeking to raise up to $86 million in an initial public offering, valuing the company at up to $475 million.
Family care website Care.com expects to raise up to $86 mln in IPOCompany files with SEC for IPO that values it at about $475 million
Family care website Care.com expects to raise up to $86 mln in IPO-ReutersCare.com Inc, an online marketplace for family care services, is seeking to raise up to $86 million in an initial public offering, valuing the company at up to $475 million, Reuters reported.
- Covidien, Lightstone, NEA back formation of medical device company
Covidien, Lightstone Ventures and New Enterprise Associates will jointly invest in a new company, FIRE1, launched by The Foundry, a medical device incubator. FIRE1, based in Dublin, Ireland, will focus on developing therapeutic devices.
- NEA hires former Bristol-Myers Squibb executive as venture partner
New Enterprise Associates has hired Elliott Sigal as venture partner and senior advisor. Sigal is a former executive vice president and director for Bristol-Myers Squibb. He worked as the company's chief scientific officer and president of research and development from 2004 to 2013.
- Elliott Sigal joins NEA's healthcare team
New Enterprise Associates has named life sciences veteran Dr. Elliott Sigal as a venture partner and senior advisor to help augment the firm's healthcare practice. Sigal is a former executive vice president and director for Bristol-Myers Squibb, where he served as the company’s Chief Scientific Officer and president of R&D from 2004 to 2013.
- VC-backed Trevena names new board member
Trevena has appointed Dr. Francois Nader to its board of directors. Dr. Nader is the president and CEO of NPS Pharmaceuticals.Based in King of Prussia, Penn., Trevena is a clinical stage biopharmaceutical company that develops therapeutics that target G protein coupled receptors. It is backed by Alta Partners, New Enterprise Associates, Polaris Partners, Forest Labs and HealthCare Ventures.
- VC-backed Cvent files for secondary offering
Cvent said Monday that it has filed to sell 4.8 million shares of its common stock in a secondary public offering. Morgan Stanley and Goldman Sachs will serve as lead underwriters. Based in McLean, Virginia, Cvent is an event management platform. Its backers include Insight Venture Partners, Greenspring Associates and New Enterprise Associates.
The final word: 2014 outlookVarious VCs and others reflect on the last year and predict what the future may bring
The incredible shrinking venture industryMany VCs believe the business has finally right-sized, but don’t place your bets too quickly